Therefore, based on the GSK-3β-mediated inhibitory role for the wnt/β-catenin pathway, we speculate that RPN2 may be implicated in GBM development and progression by regulating the GSK-3β/wnt/β-catenin pathway, which remains to be further experimentally verified. The gene discussed is RPN2; the disease is glioblastoma.